{"id":7,"date":"2015-12-28T22:08:34","date_gmt":"2015-12-29T05:08:34","guid":{"rendered":"https:\/\/blogs.ubc.ca\/wyattlab\/?page_id=7"},"modified":"2026-07-13T17:05:14","modified_gmt":"2026-07-14T00:05:14","slug":"publications","status":"publish","type":"page","link":"https:\/\/blogs.ubc.ca\/wyattlab\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"\n

An up-to-date list of our journal publications can be found\u00a0on PubMed<\/a>\u00a0or Google Scholar<\/a>. This page was last updated in July 2026.<\/p>\n\n\n\n

Significant Publications<\/h4>\n\n\n\n
\"\"<\/a><\/figure>
\n

Germline CDK12 variants in aggressive prostate cancer\u00a0
<\/a><\/strong><\/em>Cancer Discovery <\/strong>2026<\/strong>
S.H. Tolmeijer<\/em>, C. Maurice-Dror, S. Sandhu, C.M. de la Calle, C. Kollmannsberger, M. Adil, C.K. Wang, A.J. Murtha, G. Donnellan, <\/em>N.P. van Erp, N. Mehra, M.S. Hofman, A.A. Azad, I.D. Davis, A.M. Bergman, W. Zwart, K. van der Zande, L. Seymour, P.C. Black, V. Akbari, L. Cordova, P.M. Lansdorp, S.J.M. Jones, P.S. Nelson, E. Castro, K.A. Schrader, G. Ha, H.H. Cheng, P. Ost, D. Olmos, K.N. Chi, C.C. Pritchard, A.W. Wyatt<\/strong>*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer
<\/a><\/strong><\/em>Nature Communications <\/strong>2026<\/strong>
D.C. M\u00fcller\u2020<\/sup><\/em><\/em><\/em><\/em>, A.J. Murtha\u2020<\/sup><\/em><\/em><\/em><\/em>, J.V.W. Bacon, M. Stephenson,<\/em> C. Wells, C. Vasquez-Rios, K. Rostin,<\/em> L. Rebane, E. Sch\u00f6nlau, J. Nikkola, N. Alimohamed, N.S. Basappa, D. Finch, J.J. Ko, J.-M. Lavoie, L. Nappi, K. Noonan, M. Ong, G. Ozgun, S. Parimi, M. Soleimani, S.S. Sridhar, P. Toren, E. Winquist, C.Q. Bernales, M. Koudjanian, J. Atwal, E. Fung, <\/em>L. Khan, B. Eigl, D. Othman, T.A. Bismar, G. Wang, R. Merza, A.I. Papadakis, A. Spatz, C. Kollmannsberger, C. Maurice-Dror, M. Annala, K.N. Chi, G. Vandekerkhove*, A.W. Wyatt*<\/strong>, <\/em>B.J. Eigl*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Clonal Hematopoiesis after\u00a0177<\/sup>Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
<\/a>Clinical cancer research <\/strong>202<\/strong>6
A.D. Munzur, C. Herberts, E.M. Kwan,<\/em> L. Emmett, S. Sandhu, J.P. Buteau, A. Iravani, A.M. Joshua, R.J. Francis, S.-T. Lee, A.M. Scott, A.J. Martin, M.R. Stockler, A.Y. Zhang, S.G. Williams, C.Q. Bernales, G. Donnellan, M. Koudjanian, K. Parekh, J.V.W. Bacon,<\/em> A. Karsan, A.A. Azad, I.D. Davis*, M.S. Hofman*, A.W. Wyatt*<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Repertoire and clinical hierarchy of\u00a0AR<\/em>\u00a0locus alterations in castration-resistant prostate cancer
<\/a>Annals of Oncology <\/strong>2025<\/strong>
T. Virtanen\u2020<\/sup><\/em><\/em><\/em><\/em>, E.M. Kwan\u2020<\/sup><\/em><\/em><\/em><\/em>, K. Parekh, J.V.W. Bacon,<\/em> C.F. Huang, I.P.L. Yu, L. Ryypp\u00f6, C.Q. Bernales, G. Donnellan, C. Tam, J. Sipola, J. Nikkola, G. Vandekerkhove, S.H. Tolmeijer,<\/em> K. Kukkonen, Adelia, B.J. Eigl, D. Finch, R. Gagnon, Y. Takieldeen, E. Hardy, D. Khalaf, C. Kollmannsberger, J.-M. Lavoie, C. Maurice-Dror, S. Miller, L. Nappi, K. Noonan, S. Parimi, A. Riminchan, E. Sartori-Mueller, M. Soleimani, J. Vergidis, M. Zulfiqar, A. Hansen, S. Hotte, M. Jafri, M. Kolinsky, S.D. Mukherjee, M. Ong, A.A.N. Rose, W. Tu<\/em>, E. Winquist, A.M. Bergman, K. van der Zande, W. Zwart, N. Mehra, N.P. van Erp, J.L. Zhao, D. Rathkopf, C.E. Barbieri, D.A. Quigley, M. Nykter, N.A. Lack, K.N. Chi, M. Annala*, A.W. Wyatt<\/strong>*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Cabazitaxel Versus Abiraterone or Enzalutamide for Poor-prognosis Metastatic Castration-resistant Prostate Cancer After Docetaxel: A Phase 2 Trial with a Circulating Tumor DNA Analysis
<\/a>European Urology Oncology <\/strong>2025<\/strong>
K. Parekh\u2020<\/sup><\/em><\/em><\/em><\/em>, K. van der Zande\u2020<\/sup><\/em><\/em><\/em><\/em>, S.W.S. Ng, C. Herberts, E.M. Kwan, G. Vandekerkhove,<\/em> V. van der Noort, M.P.H. Busard, A. Beeker, P. van den Berg, J.M. de Feijter, V. Dezentje, P. Hamberg, D. Houtsma, S. Ras, M. Tascilar, R.D. Tutuhatunewa-Louhanepessy, Y.J.R. Liao, S.H. Tolmeijer, G. Donnellan, <\/em>K.N. Chi, A.W. Wyatt<\/strong>*, W. Zwart* , A.M. Bergman* on behalf of the OSTRICh Investigators and the Dutch Uro-Oncology Study Group (DUOS16107)<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

ERBB2<\/em>\/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer
<\/a>Clinical cancer research <\/strong>2025<\/strong>
G. Vandekerkhove\u2020<\/sup><\/em><\/em><\/em>, A.J. Murtha\u2020<\/sup><\/em><\/em><\/em>, D.C. M\u00fcller, M. Stephenson, K. Rostin, A.D. Munzur, C. Vasquez-Rios,<\/em> J. Nikkola, J. Sipola, M. Annala, C. Herberts,<\/em> E. Fung, J. Atwal, S. Al-Subaie, K. Parekh, C.Q. Bernales, G. Donnellan,<\/em> D. Finch, K. Noonan, J.J. Ko, G. Ozgun, L. Nappi, C. Kollmannsberger, J.-M. Lavoie, S. Parimi, T. Todenh\u00f6fer, P. Ost, G. Wang, P.C. Black, C. Maurice-Dror, K.N. Chi, B.J. Eigl*, A.W. Wyatt* <\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma
<\/a>JCO Precision Oncology<\/strong> 2025<\/strong>
A.D. Munzur<\/em>, J.V.W. Bacon,<\/em> F. Fishbein, C. Herberts,<\/em> G. Donnellan, C.Q. Bernales, K. Parekh, G. Vandekerkhove, D.C. M\u00fcller, Y.J.R. Liao, M. Stephenson, L. <\/em>Nappi, D. Khalaf, C. Maurice-Dror, K.N. Chi, B.J. Eigl, C. Kollmannsberger, M. Soleimani, A.W. Wyatt <\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Lutetium-177\u2013PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
<\/a>Nature <\/strong>Medicine 2025<\/strong>
E.M. Kwan\u2020<\/sup><\/em><\/em>, S.W.S. Ng\u2020<\/sup><\/em><\/em>, S.H. Tolmeijer, <\/em>L. Emmett, S. Sandhu, J.P. Buteau, A. Iravani, A.M. Joshua, R.J. Francis, V. Subhash, S.T. Lee, A.M. Scott, A.J. Martin, M.R. Stockler, G. Donnellan, M. Annala, C. Herberts,<\/em> I.D. Davis, M.S. Hofman, A.A. Azad, A.W. Wyatt<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer
<\/a>Clinical Cancer Research<\/strong> 2025<\/strong>
E. Winquist, S.J. Hotte, K. Chi, S. Sridhar, S. Ellard, M. Ong, N. Iqbal, M. Salim, U. Emmenegger, J.R. Gingerich, A.K. Lalani, P. Major, C. Kollmannsberger, S. Yip, A. Hansen, D. Finch, C. Canil, J. Hutchenreuther, F. Vera-Badillo, M. Smoragiewicz, M. Cabanero, M.S. Tsao, E. Ritch<\/em>, A.W. Wyatt<\/strong>*, L. Seymour*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer
<\/a>Cancer Research<\/strong> 2025 <\/strong>
J. Sipola\u2020<\/sup><\/em>, A.D. Munzur\u2020<\/sup><\/em>, E.M. Kwan\u2020<\/sup><\/em>,<\/em> C.C.Y. Seo, B.J. Hauk, K. Parekh, Y.J.R. Liao, C.Q. Bernales, G. Donnellan, <\/em>I. Bloise, E. Fung, S.W.S. Ng,<\/em> G. Wang, G. Vandekerkhove, <\/em>M. Nykter, M. Annala, <\/em>C. Maurice-Dror, K.N. Chi, C. Herberts*,<\/em> A.W. Wyatt<\/strong>*, D.Y. Takeda*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group.
<\/a>Clinical Cancer Research<\/strong> 2024<\/strong>
A.W. Wyatt*, <\/strong>S. Litiere, F.C. Bidard, L. Cabel, L. Dyrskj\u00f8t, C.A. Karlovich, K. Pantel, J. Petrie, R. Philip, H.S. Andrews, P.J. Vellanki, S.H. Tolmeijer,<\/em> X. Villalobos Alberu, C. Alfano, J. Bogaerts, E. Calvo, A.P. Chen, R.A. Toledo, E.G.E. de Vries, L. Seymour, S.A. Laurie*, E. Garralda*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer
<\/a>JCO Precision Oncology<\/strong> 2024<\/strong>
G. Vandekerkhove<\/em>, V.N. Giri, S. Halabi, C. McNair, K. Hamade, R.L. Bitting, and A.W. Wyatt*<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
<\/a>Nature Communications 2024<\/strong>
N.M. Fonseca\u2020<\/sup><\/em>, C. Maurice-Dror\u2020<\/sup><\/em>, C. Herberts\u2020<\/sup><\/em>, W. Tu,<\/em> W. Fan, A.J. Murtha,<\/em> C. Kollmannsberger, E.M. Kwan, K. Parekh, E. Sch\u00f6nlau, C.Q. Bernales, G. Donnellan, S.W.S. Ng, T. Sumiyoshi<\/em>, J. Vergidis, K. Noonan, D.L. Finch, M. Zulfiqar, S. Miller, S. Parimi, J-M. Lavoie, E. Hardy, M. Soleimani, L. Nappi, B.J. Eigl, C. Kollmannsberger, S. Taavitsainen, M. Nykter, S.H. Tolmeijer<\/em>, E. Boerrigter, N. Mehra, N.P. van Erp, B. De Laere, J. Lindberg, H. Gr\u00f6nberg, D.J. Khalaf, M. Annala<\/em>*, K.N. Chi* and A.W. Wyatt*<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping
<\/a>Nature Cancer 2024<\/strong>
E.W. Warner\u2020<\/sup><\/em>, K. Van der Eecken\u2020<\/sup><\/em>, A.J. Murtha\u2020<\/sup><\/em>, E.M. Kwan, C. Herberts, J. Sipola, S.W.S. Ng, X.E. Chen, N.M. Fonseca, E. Ritch, E. Sch\u00f6nlau, C.Q. Bernales, G. Donnellan, A.D. Munzur, K. Parekh, K. Beja, A. Wong,<\/em> S. Verbeke, N. Lumen, J. Van Dorpe, B. De Laere, M. Annala, G. Vandekerkhove,<\/em> P. Ost* and A.W. Wyatt*<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Molecular features of prostate cancer after neoadjuvant therapy in the phase 3 CALGB 90203 trial<\/a>
<\/a>JNCI 2023<\/strong>
T. Sumiyoshi<\/em>, X. Wang, E.W. Warner<\/em>, A. Sboner, M. Annala,<\/em> M. Sigouros, K. Beja,<\/em> K. Mizuno, S. Ku, L. Fazli, J. Eastham, M-E Taplin, J. Simko, S. Halabi, M.J. Morris, M.E. Gleave, A.W. Wyatt*<\/strong>, and H. Beltran*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes<\/a>
NPJ Precision Oncology 2023<\/strong>
E.J. Ritch, C. Herberts, E.W. Warner, S.W.S. Ng, E.M. Kwan, J.V.W. Bacon, C.Q. Bernales, E. Sch\u00f6nlau, N.M. Fonseca,<\/em> V.N. Giri, C. Maurice-Dror, G. Vandekerkhove,<\/em> S.J.M. Jones, K.N. Chi, and A.W. Wyatt<\/strong>*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer<\/strong><\/a>
Clinical Cancer Research 202<\/strong>3
S.H. Tolmeijer\u2020<\/sup><\/em>, E. Boerrigter\u2020<\/sup><\/em>, T. Sumiyoshi<\/em>, E.M. Kwan, S.W.S. Ng, M. Annala, G. Donnellan, C. Herberts,<\/em> G.E. Benoist, P. Hamberg, D.M. Somford, I.M. van Oort, J.A. Schalken, N. Mehra1*, N.P. van Erp*, and A.W. Wyatt<\/strong>*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer<\/a>
Nature 2022<\/strong>
C. Herberts\u2020<\/sup><\/em>, M. Annala\u2020<\/sup><\/em>, J. Sipola\u2020<\/sup><\/em>, S.W.S. Ng<\/em>, X.E. Chen<\/em>, A. Nurminen, O.V. Korhonen, A.D. Munzur<\/em>, K. Beja, E. Sch\u00f6nlau, C.Q. Bernales, Elie Ritch, J.V.W. Bacon,<\/em> N.A. Lack, M. Nykter, R. Aggarwal, E.J. Small, M.E. Gleave, SU2C\/PCF West Coast Prostate Cancer Dream Team, D.A. Quigley, F.Y. Feng, K.N. Chi & A.W. Wyatt<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer
<\/a>The Prostate 2022<\/strong>
E.M. Kwan<\/em> & A.W. Wyatt<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer<\/a>
<\/a>JCO Precision Oncology 2022<\/strong>
N.M. Fonseca\u2020<\/sup><\/em>, K. Van der Eecken\u2020<\/sup><\/em>, C. Herberts\u2020<\/sup><\/em>, S. Verbeke, S.W.S. Ng<\/em>, N. Lumen, E. Ritch<\/em>, A.J. Murtha<\/em>, C.Q. Bernales, E. Sch\u00f6nlau<\/em>, L. Moris, J. Van Dorpe, M. Annala<\/em>, A.W. Wyatt*<\/strong>, P. Ost*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Somatic Features of Response and Relapse in Non\u2013muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin Immunotherapy<\/a>
<\/a>European Urology Oncology 2021<\/strong>
J.V.W. Bacon\u2020<\/sup><\/em>, D.C. M\u00fcller\u2020<\/sup><\/em>, E. Ritch<\/em>, M. Annala<\/em>, S.G. Dugas, C. Herberts,<\/em> G. Vandekerkhove,<\/em> H. Seifert, T. Zellweger, P.C. Black, L. Bubendorf, A.W. Wyatt<\/strong>*, C.A. Rentsch*<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Evolution of castration-resistant prostate cancer in ctDNA during sequential androgen receptor pathway inhibition<\/strong><\/a>
Clinical Cancer Research 2021<\/strong><\/p>\n\n\n\n

M. Annala<\/em>, S. Taavitsainen, D.J. Khalaf, G. Vandekerkhove<\/em>, K. Beja<\/em>, J. Sipola, E.W. Warner, C. Herberts<\/em>, A. Wong<\/em>, S. Fu, D.L. Finch, C.D. Oja, J. Vergidis, Muhammad Zulfiqar, Bernhard J. Eigl, C.K. Kollmansberger, M. Nykter, M. E. Gleave, K. N. Chi, A.W. Wyatt<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial<\/strong><\/a>
Annals of Oncology 2021<\/strong>
M. Annala<\/em>, S. Fu, J.V.W. Bacon<\/em>, J. Sipola, N. Iqbal, C. Ferrario, M. Ong, D. Wadhwa, S.J. Hotte, G. Lo, B. Tran, L.A. Wood, <\/sup>J.R. Gingerich, S.A. North, C.J. Pezaro, J.D. Ruether, S.S. Sridhar, H.M.L. Kallio, D.J. Khalaf, A. Wong, K. Beja, E. Sch\u00f6nlau, S. Taavitsainen<\/em>, M. Nykter, G. Vandekerkhove<\/em>, A.A. Azad, A.W. Wyatt,<\/strong> K.N. Chi,<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Technical and biological constra<\/strong><\/a>ints on ctDNA-based genotyping<\/a><\/strong>
Trends in Cancer 2021<\/strong>
C. Herberts <\/em>and A.W.Wyatt<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer<\/a><\/strong>
<\/a>Nature Communication 2021<\/strong>
Vandekerkhove G<\/em>, Lavoie J, Annala M, Murtha AJ<\/em>, Sundahl N, Walz S, Sano T, Taavitsainen S, Ritch E<\/em>, Fazli L, Hurtado-Coll A, Wang G, Nykter M, Black PC, Todenhofer T, Ost P, Gibb EA, Chi KN, Eigl BJ, Wyatt AW<\/strong>.<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression
<\/a>Clinical Cancer Research 2021<\/strong>
<\/strong>Warner E\u2020<\/em>, Herberts C\u2020<\/em>, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, Vandekerkhove G, Fonseca NM, Angeles A, Beigi A, Sch\u00f6nlau E, Beja K, Annala M, Khalaf D, Chi K, Wyatt AW<\/strong>. \u2020 denotes co-first authors<\/em><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
<\/a>European Urology 2020
<\/strong><\/strong><\/strong>Herberts C\u2020, Murtha AJ\u2020<\/em>, Fu S, Wang G, Sch\u00f6nlau E<\/em>, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E<\/em>, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M<\/em>, Chi KN, Wyatt AW.<\/strong> \u2020 denotes co-first authors<\/em><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer<\/a>
Clinical Cancer Research 2020<\/strong>
<\/strong><\/strong><\/strong>Ritch E\u2020<\/em>, Fu SYF\u2020<\/em>, Herberts C\u2020<\/em>, Wang G, Warner EW, Sch\u00f6nlau E, Taavitsainen S, Murtha AJ, Vandekerkhove G, Beja K, Loktionova Y, Khalaf D,<\/em> Fazli L, Kushnir I, Ferrario C, Hotte S, Annala M, <\/em>Chi KN, Wyatt AW<\/strong>.  \u2020 denotes co-first authors<\/em><\/em><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial<\/a>
Lancet Oncology 2019<\/strong>
<\/strong><\/strong><\/strong>Khalaf DJ\u2020<\/em>, Annala M\u2020<\/em>, Taavitsainen S,<\/em> Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME,<\/strong> Wyatt AW, Chi KN. <\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer<\/a>
European Urology 2019<\/strong>
<\/strong><\/strong><\/strong>Vandekerkhove G<\/em>, Struss WJ<\/em>, Annala M<\/em>, Kallio HML, Khalaf D<\/em>, Warner EW<\/em>, Herberts C<\/em>, Ritch E<\/em>, Beja K<\/em>, Loktionova Y<\/em>, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW.<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer<\/a>
Cancer Discovery 2018<\/strong>
<\/strong><\/strong><\/strong>Annala M<\/em>, Vandekerkhove G<\/em>, Khalaf D<\/em>, Taavitsainen S<\/em>, Beja K<\/em>, Warner EW<\/em>, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW,<\/strong> Chi KN<\/p>\n<\/div><\/div>\n\n\n\n

\"Liquid<\/a><\/figure>
\n

<\/a>Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer<\/a>
Journal of the National Cancer Institute 2017
<\/strong><\/strong><\/strong>Wyatt AW,<\/strong> Annala M<\/em>, Aggarwal R, Beja K<\/em>, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME<\/p>\n<\/div><\/div>\n\n\n\n

\"\"<\/a><\/figure>
\n

<\/a>Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer<\/a>
Clinical Cancer Research 2017<\/strong>
<\/strong><\/strong><\/strong>Vandekerkhove G<\/em>, Todenh\u00f6fer T, Annala M<\/em>, Struss WJ<\/em>, Wong A<\/em>, Beja K<\/em>, Ritch E<\/em>, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW.<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"Annala<\/a><\/figure>
\n

<\/a>Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer<\/a>
European Urology 2017<\/strong>
<\/strong><\/strong><\/strong>Annala M<\/em>, Struss WJ<\/em>, Warner EW<\/em>, Beja K<\/em>, Vandekerkhove G<\/em>, Wong A<\/em>, Khalaf D<\/em>, Sepp\u00e4l\u00e4 IL<\/em>, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW<\/strong><\/p>\n<\/div><\/div>\n\n\n\n

\"Genomic<\/a><\/figure>
\n

<\/a>Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer
<\/strong><\/a>JAMA Oncology 2016
<\/strong><\/strong><\/strong>Wyatt AW,<\/strong> Azad AA, Volik SV, Annala M<\/em>, Beja K<\/em>, McConeghy B, Haegert A, Warner EW<\/em>, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN.<\/p>\n<\/div><\/div>\n\n\n\n

All Articles<\/h4>\n\n\n\n

2025<\/strong><\/p>\n\n\n\n

Munzur AD, Bacon JVW, Fishbein F, Herberts C, Donnellan G, Bernales CQ, Parekh K, Vandekerkhove G, M\u00fcller DC, Liao YJR, Stephenson M, Nappi L, Khalaf D, Maurice-Dror C, Chi KN, Eigl BJ, Kollmannsberger C, Soleimani M, Wyatt AW<\/strong> (corresponding author)<\/strong>. Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma. NPJ Precis Oncol. 2025 <\/u><\/em><\/strong>Jun 13;9(1):177. doi: 10.1038\/s41698-025-00965-y. PubMed PMID: 40514379.<\/p>\n\n\n\n

Kwan EM, Ng SWS, Tolmeijer SH, Emmett L, Sandhu S, Buteau JP, Iravani A, Joshua AM, Francis RJ, Subhash V, Lee ST, Scott AM, Martin AJ, Stockler MR, Donnellan G, Annala M, Herberts C, Davis ID, Hofman MS, Azad AA, Wyatt AW (corresponding author)<\/strong>. Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial. Nat Med. 2025<\/u><\/em><\/strong> May 27;. doi: 10.1038\/s41591-025-03704-9. [Epub ahead of print] PubMed PMID: 40425844.<\/p>\n\n\n\n

Bitting RL, McNair C, Wyatt AW<\/strong>, Vandekerkhove G, Choi T, Leader AE, Blanding-Godbolt J, Gross L, Hamade K, Halabi S, Giri VN. Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey. JCO Precis Oncol. 2025 May;9:e2400821. doi: 10.1200\/PO-24-00821. Epub 2025 May 15. PubMed PMID: 40373262.<\/p>\n\n\n\n

Fadlullah MZH, Nix D, Herberts C, Maurice-Dror C, Wyatt AW<\/strong>, Schmidt B, Fairbourn B, Tan AC, Wang L, Kohli M. Multi-gene risk-score for prediction of clinical outcomes in treatment-na\u00efve metastatic castrate resistant prostate cancer. JNCI Cancer Spectr. 2025<\/u><\/em><\/strong> Feb 28;. doi: 10.1093\/jncics\/pkaf025. [Epub ahead of print] PubMed PMID: 40036789.<\/p>\n\n\n\n

Eifer M, Sutherland DEK, Goncalves I, Buteau JP, Au L, Azad AA, Emmett L, Kong G, Kostos L, Ravi Kumar AS, Kwan EM, Medhurst E, Sandhu S, Tran B, Wyatt AW<\/strong>, Hofman MS. Therapy-Related Myeloid Neoplasms After [(177)Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series. J Nucl Med. 2025<\/u><\/em><\/strong> Feb 20;. doi: 10.2967\/jnumed.124.268640. [Epub ahead of print] PubMed PMID: 39978813.<\/p>\n\n\n\n

Winquist E, Hotte SJ, Chi K, Sridhar S, Ellard S, Ong M, Iqbal N, Salim M, Emmenegger U, Gingerich JR, Lalani AK, Major P, Kollmannsberger C, Yip S, Hansen A, Finch D, Canil C, Hutchenreuther J, Vera-Badillo F, Smoragiewicz M, Cabanero M, Tsao MS, Ritch E, Wyatt AW (co-senior author)<\/strong>, Seymour L. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2025<\/u><\/em><\/strong> Jan 6;31(1):45-55. doi: 10.1158\/1078-0432.CCR-24-1612. PubMed PMID: 39513948.<\/p>\n\n\n\n

Nikkola J, Ryypp\u00f6 L, Vuorinen J, Kallio H, Selin H, J\u00e4ms\u00e4 P, \u00c5kerla J, Virtanen T, Pekkarinen T, Kaipia A, Pulkkinen J, Vandekerkhove G, M\u00fcller DC, Wyatt AW<\/strong>, Black PC, Nykter M, Veitonm\u00e4ki T, Annala M. Sensitive Detection of Urothelial Cancer via High-volume Urine DNA Analysis. Eur Urol. 2025<\/u><\/em><\/strong> Jan;87(1):86-88. doi: 10.1016\/j.eururo.2024.10.014. Epub 2024 Oct 22. PubMed PMID: 39443274.<\/p>\n\n\n\n

2024<\/strong><\/p>\n\n\n\n

Sipola J, Munzur AD, Kwan EM, Seo CCY, Hauk BJ, Parekh K, Liao YJR, Bernales CQ, Donnellan G, Bloise I, Fung E, Ng SWS, Wang G, Vandekerkhove G, Nykter M, Annala M, Maurice-Dror C, Chi KN, Herberts C, Wyatt AW (corresponding author)<\/strong>, Takeda DY. Plasma cell-free DNA chromatin immunoprecipitation profiling depicts phenotypic and clinical heterogeneity in advanced prostate cancer. Cancer Res. 2024<\/u><\/em><\/strong> Dec 9;. doi: 10.1158\/0008-5472.CAN-24-2052. [Epub ahead of print] PubMed PMID: 39652574.<\/p>\n\n\n\n

Wyatt AW (corresponding author)<\/strong>, Litiere S, Bidard FC, Cabel L, Dyrskj\u00f8t L, Karlovich CA, Pantel K, Petrie J, Philip R, Andrews HS, Vellanki PJ, Tolmeijer SH, Villalobos Alberu X, Alfano C, Bogaerts J, Calvo E, Chen AP, Toledo RA, de Vries EGE, Seymour L, Laurie SA, Garralda E. Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working Group. Clin Cancer Res. 2024<\/u><\/em><\/strong> Nov 15;30(22):5034-5041. doi: 10.1158\/1078-0432.CCR-24-1883. Review. PubMed PMID: 39269996.<\/p>\n\n\n\n

Monjaras-Avila CU, Luque-Badillo AC, Bacon JVM, Wyatt AW<\/strong>, So A, Chavez-Munoz C. A novel approach to engineering three-dimensional bladder tumor models for drug testing. Sci Rep. 2024 Nov 6;14(1):26883. doi: 10.1038\/s41598-024-78440-0. PubMed PMID: 39506094; PubMed Central PMCID: PMC11542063.<\/p>\n\n\n\n

Zhao SG, Bootsma M, Zhou S, Shrestha R, Moreno-Rodriguez T, Lundberg A, Pan C, Arlidge C, Hawley JR, Foye A, Weinstein AS, Sj\u00f6str\u00f6m M, Zhang M, Li H, Chesner LN, Rydzewski NR, Helzer KT, Shi Y, Lynch M, Dehm SM, Lang JM, Alumkal JJ, He HH, Wyatt AW<\/strong>, Aggarwal R, Zwart W, Small EJ, Quigley DA, Lupien M, Feng FY. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nature Genetics 2024<\/u><\/em><\/strong> Aug;56(8):1689-1700. doi: 10.1038\/s41588-024-01826-3. Epub 2024 Jul 17. PubMed PMID: 39020220; PubMed Central PMCID: PMC11319208.<\/p>\n\n\n\n

Mahal BA, Margolis M, Hubbell E, Chen C, Venstrom JM, Abran J, Kartlitz JJ, Wyatt AW<\/strong>, Klein EA. A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. JCO Precis Oncol. 2024<\/u><\/em><\/strong> Aug;8:e2400269. doi: 10.1200\/PO.24.00269. PubMed PMID: 39208374; PubMed Central PMCID: PMC11371104.<\/p>\n\n\n\n

McConkey DJ, Baumann BC, Cooper Greenberg S, DeGraff DJ, Delacroix SE, Efstathiou JA, Foster J, Groshen S, Kadel EE, Khani F, Kim WY, Lerner SP, Levin T, Liao JC, Milowsky MI, Meeks JJ, Miyamoto DT, Mouw KW, Pietzak EJ, Solit DB, Sundi D, Tawab-Amiri A, West PJ, Wobker SE, Wyatt AW<\/strong>, Apolo AB, Black PC. Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer. Bladder Cancer. 2024<\/u><\/em><\/strong>;10(1):1-8. doi: 10.3233\/BLC-230082. eCollection 2024. PubMed PMID: 38993535; PubMed Central PMCID: PMC11181871.<\/p>\n\n\n\n

Vandekerkhove G, Giri VN, Halabi S, McNair C, Hamade K, Bitting RL, Wyatt AW <\/strong>(corresponding author<\/strong>). Toward Informed Selection and Interpretation of Clinical Genomic Tests in Prostate Cancer. JCO Precis Oncol. 2024 <\/u><\/em><\/strong>Mar;8:e2300654. doi: 10.1200\/PO.23.00654. PMID: 38547422.<\/p>\n\n\n\n

Fonseca NM, Maurice-Dror C, Herberts C, Tu W, Fan W, Murtha AJ, Kollmannsberger C, Kwan EM, Parekh K, Sch\u00f6nlau E, Bernales CQ, Donnellan G, Ng SWS, Sumiyoshi T, Vergidis J, Noonan K, Finch DL, Zulfiqar M, Miller S, Parimi S, Lavoie JM, Hardy E, Soleimani M, Nappi L, Eigl BJ, Kollmannsberger C, Taavitsainen S, Nykter M, Tolmeijer SH, Boerrigter E, Mehra N, van Erp NP, De Laere B, Lindberg J, Gr\u00f6nberg H, Khalaf DJ, Annala M, Chi KN, Wyatt AW<\/strong> (corresponding author<\/strong>). Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nat Commun. 2024 <\/u><\/em><\/strong>Feb 28;15(1):1828. doi: 10.1038\/s41467-024-45475-w. PMID: 38418825.<\/p>\n\n\n\n

Warner EW, Van der Eecken K, Murtha AJ, Kwan EM, Herberts C, Sipola J, Ng SWS, Chen XE, Fonseca NM, Ritch E, Sch\u00f6nlau E, Bernales CQ, Donnellan G, Munzur AD, Parekh K, Beja K, Wong A, Verbeke S, Lumen N, Van Dorpe J, De Laere B, Annala M, Vandekerkhove G, Ost P, Wyatt AW<\/strong> (corresponding author<\/strong>). Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat Cancer. 2024 <\/u><\/em><\/strong>Jan;5(1):114-130. doi: 10.1038\/s43018-023-00692-y. Epub 2024 Jan 4. PMID: 38177459.<\/p>\n\n\n\n

Zhao JL, Antonarakis ES, Cheng HH, George DJ, Aggarwal R, Riedel E, Sumiyoshi T, Schonhoft JD, Anderson A, Mao N, Haywood S, Decker B, Curley T, Abida W, Feng FY, Knudsen K, Carver B, Lacouture ME, Wyatt AW<\/strong>, Rathkopf D. Phase 1b study of enzalutamide plus CC-115, a dual mTORC1\/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). Br J Cancer. 2024<\/u><\/em><\/strong> Jan;130(1):53-62. doi: 10.1038\/s41416-023-02487-5. PMID: 37980367.<\/p>\n\n\n\n

Sumiyoshi T, Wang X, Warner EW, Sboner A, Annala M, Sigouros M, Beja K, Mizuno K, Ku S, Fazli L, Eastham J, Taplin ME, Simko J, Halabi S, Morris MJ, Gleave ME, Wyatt AW (co-senior author)<\/strong>, Beltran H. Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial. J Natl Cancer Inst. 2024<\/u><\/em><\/strong> Jan 10;116(1):115-126. doi: 10.1093\/jnci\/djad184. PMID: 37676819.<\/p>\n\n\n\n

2023<\/strong><\/p>\n\n\n\n

Schostak M, Bradbury A, Briganti A, Gonzalez D, Gomella L, Mateo J, Penault-Llorca F, Stenzinger A, Wyatt AW<\/strong>, Bjartell A. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. Eur Urol Oncol. 2023<\/u><\/em><\/strong> Sep 13;. doi: 10.1016\/j.euo.2023.08.004. [Epub ahead of print] Review. PubMed PMID: 37714762.<\/p>\n\n\n\n

Rendon RA, Selvarajah S, Wyatt AW<\/strong>, Kolinsky M, Schrader KA, Fleshner NE, Kinnaird A, Merrimen J, Niazi T, Saad F, Shayegan B, Wood L, Chi KN, Black P, Sridhar S, Yip S. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer. Can Urol Assoc J. 2023<\/u><\/em><\/strong> Oct;17(10):314-325. doi: 10.5489\/cuaj.8588. PMID: 37851913.<\/p>\n\n\n\n

Wyatt AW (corresponding author)<\/strong>. Rare Genetic Drivers of Lethal Prostate Cancer. JAMA Oncol. 2023<\/u><\/em><\/strong> Nov 1;9(11):1499-1501. doi: 10.1001\/jamaoncol.2023.3352. PMID: 37733349.<\/p>\n\n\n\n

Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, Reese SR, Taylor A, Kaufmann KR, Krause HK, Schehr JL, Sethakorn N, Kosoff D, Kyriakopoulos C, Burkard ME, Rydzewski NR, Yu M, Harari PM, Bassetti M, Blitzer G, Floberg J, Sj\u00f6str\u00f6m M, Quigley DA, Dehm SM, Armstrong AJ, Beltran H, McKay RR, Feng FY, O’Regan R, Wisinski KB, Emamekhoo H, Wyatt AW<\/strong>, Lang JM, Zhao SG. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023<\/u><\/em><\/strong> Sep;34(9):813-825. doi: 10.1016\/j.annonc.2023.06.001. PMID: 37330052.<\/p>\n\n\n\n

Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sj\u00f6str\u00f6m M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW<\/strong>, Feng FY, Small EJ, Quigley DA. The genomic and epigenomic landscape of double-negative metastatic prostate cancer. Cancer Res. 2023<\/u><\/em><\/strong> Aug 15;83(16):2763-2774. doi: 10.1158\/0008-5472.CAN-23-0593. PMID: 37289025.<\/p>\n\n\n\n

Tortora D, Roberts ME, Kumar G, Kotapalli SS, Ritch E, Scurll JM, McConeghy B, Sinha S, Wyatt AW<\/strong>, Black PC, Daugaard M. A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. iScience. 2023<\/u><\/em><\/strong> May 19;26(5):106525. doi: 10.1016\/j.isci.2023.106525. eCollection 2023 May 19. PMID: 37250326.<\/p>\n\n\n\n

Herberts C, Wyatt AW<\/strong>, Nguyen PL, Cheng HH. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair. Am Soc Clin Oncol Educ Book. 2023<\/u><\/em><\/strong> May;43:e390384. doi: 10.1200\/EDBK_390384. PMID: 37207301.<\/p>\n\n\n\n

Tolmeijer SH, Boerrigter E, Sumiyoshi T, Kwan EM, Ng S, Annala M, Donnellan G, Herberts C, Benoist GE, Hamberg P, Somford DM, van Oort IM, Schalken JA, Mehra N, van Erp NP, Wyatt AW (corresponding author)<\/strong>. Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2023<\/u><\/em><\/strong> Aug 1;29(15):2835-2844. doi: 10.1158\/1078-0432.CCR-22-2998. PMID: 36996325.<\/p>\n\n\n\n

Ritch EJ, Herberts C, Warner EW, Ng SWS, Kwan EM, Bacon JVW, Bernales CQ, Sch\u00f6nlau E, Fonseca NM, Giri VN, Maurice-Dror C, Vandekerkhove G, Jones SJM, Chi KN, Wyatt AW (corresponding author)<\/strong>. A generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes. NPJ Precis Oncol. 2023<\/u><\/em><\/strong> Mar 13;7(1):27. doi: 10.1038\/s41698-023-00366-z. PMID: 36914848.<\/p>\n\n\n\n

Kwan EM, Wyatt AW<\/strong>, Chi KN. Towards clinical implementation of circulating tumor DNA in metastatic prostate cancer: Opportunities for integration and pitfalls to interpretation. Front Oncol. 2022<\/u><\/em><\/strong>;12:1054497. doi: 10.3389\/fonc.2022.1054497. eCollection 2022. Review. PMID: 36439451.<\/p>\n\n\n\n

Christensen E, Wyatt AW<\/strong>, Galsky MD, Grivas P, Seiler R, Nawroth R, Goebell PJ, Schmitz-Drager BJ, Williams SB, Black PC, Kamat AM, Todenh\u00f6fer T, Dyrskj\u00f8t L. IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancer. Urol Oncol. 2023<\/u><\/em><\/strong> Jul;41(7):318-322. doi: 10.1016\/j.urolonc.2022.11.008. Review. PMID: 36437155.<\/p>\n\n\n\n

2022<\/strong><\/p>\n\n\n\n

Sj\u00f6str\u00f6m M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW<\/strong> (co-senior author)<\/strong>, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022<\/u><\/em><\/strong> Nov 2;82(21):3888-3902. doi: 10.1158\/0008-5472.CAN-22-1123. PMID: 36251389.<\/p>\n\n\n\n

Chen S, Petricca J, Ye W, Guan J, Zeng Y, Cheng N, Gong L, Shen SY, Hua JT, Crumbaker M, Fraser M, Liu S, Bratman SV, van der Kwast T, Pugh T, Joshua AM, De Carvalho DD, Chi KN, Awadalla P, Ji G, Feng F, Wyatt AW<\/strong> (co-corresponding author)<\/strong>, He HH. The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors. Nat Commun. 2022<\/u><\/em><\/strong> Oct 29;13(1):6467. doi: 10.1038\/s41467-022-34012-2. PMID: 36309516.<\/p>\n\n\n\n

Bacon JVW, Giannatempo P, Cataldo G, Fazli L, Saxena N, Ozgun G, Soleimani M, Chi K, Nichols C, Necchi A, Wyatt AW<\/strong>, Kollmannsberger CK, Nappi L. TP53 Alterations Are Associated With Poor Survival in Patients With Primary Mediastinal Nonseminoma Germ Cell Tumors. Oncologist. 2022<\/u><\/em><\/strong> Nov 3;27(11):e912-e915. doi: 10.1093\/oncolo\/oyac197. PMID: 36166584.<\/p>\n\n\n\n

Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A<\/strong>, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. J Clin Oncol. 2022<\/u><\/em><\/strong> Oct 10;40(29):3377-3382. doi: 10.1200\/JCO.22.00644. PMID: 36001857.<\/p>\n\n\n\n

Herberts C, Annala M, Sipola J, Ng SWS, Chen XE, Nurminen A, Korhonen OV, Munzur AD, Beja K, Sch\u00f6nlau E, Bernales CQ, Ritch E, Bacon JVW, Lack NA, Nykter M, Aggarwal R, Small EJ, Gleave ME, Quigley DA, Feng FY, Chi KN, Wyatt AW (corresponding author)<\/strong>. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. Nature. 2022<\/u><\/em><\/strong> Aug;608(7921):199-208. doi: 10.1038\/s41586-022-04975-9. PMID: 35859180.<\/p>\n\n\n\n

Sutera P, Deek MP, Van der Eecken K, Wyatt AW<\/strong>, Kishan AU, Molitoris JK, Ferris MJ, Siddiqui MM, Rana Z, Mishra MV, Kwok Y, Davicioni E, Spratt DE, Ost P, Feng FY, Tran PT. Genomic biomarkers to guide precision radiotherapy in prostate cancer. Prostate. 2022<\/u><\/em><\/strong> Aug;82 Suppl 1:S73-S85. doi: 10.1002\/pros.24373. Review. PMID: 35657158.<\/p>\n\n\n\n

Kwan EM, Wyatt AW (corresponding author)<\/strong>. Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. Prostate. 2022<\/u><\/em><\/strong> Aug;82 Suppl 1:S25-S36. doi: 10.1002\/pros.24356. Review. PMID: 35657159.<\/p>\n\n\n\n

Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, Leone G, Xiang JZ, Wingate A, Tagawa S, Jayaram A, Linch M, Jamal-Hanjani M, Swanton C, Rubin MA, Wyatt AW<\/strong>, Beltran H, Attard G, Demichelis F. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer. 2022<\/u><\/em><\/strong> Jun;4(2):zcac016. doi: 10.1093\/narcan\/zcac016. PMID: 35664542<\/p>\n\n\n\n

Fonseca NM, Van der Eecken K, Herberts C, Verbeke S, Ng SWS, Lumen N, Ritch E, Murtha AJ, Bernales CQ, Sch\u00f6nlau E, Moris L, Van Dorpe J, Annala M, Wyatt AW (co-corresponding author)<\/strong>, Ost P. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate Cancer. JCO Precis Oncol. 2022<\/u><\/em><\/strong> Apr;6:e2100543. doi: 10.1200\/PO.21.00543. PubMed PMID: 35507889.<\/p>\n\n\n\n

Di Lalla V, Kucharczyk MJ, Wyatt AW<\/strong>, Feng FY, Probst S, Gravis G, So J, Saad F, Niazi T. Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. Eur Urol. 2022<\/u><\/em><\/strong> May;81(5):437-439. doi: 10.1016\/j.eururo.2021.12.038. PMID: 35065838.<\/p>\n\n\n\n

Bacon JVW, M\u00fcller DC, Ritch E, Annala M, Dugas SG, Herberts C, Vandekerkhove G, Seifert H, Zellweger T, Black PC, Bubendorf L, Wyatt AW (co-corresponding author)<\/strong>, Rentsch CA. Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Gu\u00e9rin Immunotherapy. Eur Urol Oncol. 2022<\/u><\/em><\/strong> Dec;5(6):677-686. doi: 10.1016\/j.euo.2021.11.002. PMID: 34895867.<\/p>\n\n\n\n

Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW<\/strong>, Saad F. Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Can Urol Assoc J. 2022<\/u> <\/em><\/strong>Apr;16(4):132-143. doi: 10.5489\/cuaj.7621. Review. PMID: 34812730.<\/p>\n\n\n\n

2021<\/h5>\n\n\n\n

Van der Eecken K, Vanwelkenhuyzen J, Deek MP, Tran PT, Warner E, Wyatt AW<\/strong>, Kwan EM, Verbeke S, Van Dorpe J, Fonteyne V, Lumen N, De Laere B, Ost P. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review. Eur Urol Oncol. 2021<\/u><\/em><\/strong> Dec;4(6):914-923. doi: 10.1016\/j.euo.2021.10.005. Review. PMID: 34801437.<\/p>\n\n\n\n

Lavoie J.M., Vandekerkhove G<\/em>., Murtha A.J.<\/em>, Wang G., Wyatt A.W.<\/strong>, Eigl B.J. Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. <\/a>Urol Case Rep. 2021 doi: 10.1016\/j.eucr.2021.101762. <\/p>\n\n\n\n

Lavoie J.M., Vandekerkhove G<\/em>., Murtha A.J.<\/em>, Wang G., Wyatt A.W.<\/strong>, Eigl B.J. Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors. <\/a>Urol Case Rep. 2021 doi: 10.1016\/j.eucr.2021.101762. <\/p>\n\n\n\n

Gonzalez D, Mateo J, Stenzinger A, Rojo F, Shiller M, Wyatt AW<\/strong>, Penault-Llorca F, Gomella LG, Eeles R, Bjartell A. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. <\/a>J Pathol Clin Res. 2021 Jul. doi: 10.1002\/cjp2.203<\/p>\n\n\n\n

Dror CM, Wyatt AW<\/strong>, Chi KN. Olaparib for the treatment of metastatic prostate cancer. <\/a>Future Oncol. 2021 Jul. doi: 10.2217\/fon-2020-1245<\/p>\n\n\n\n

Annala M,<\/em> Fu S, Bacon JVW,<\/em> Sipola J, Iqbal N, Ferrario C, Ong M, Wadhwa D, Hotte SJ, Lo G, Tran B, Wood LA, Gingerich JR, North SA, Pezaro CJ, Ruether JD, Sridhar SS, Kallio HML, Khalaf DJ, Wong A, Beja K, Sch\u00f6nlau E, Taavitsainen S,<\/em> Nykter M, Vandekerkhove G,<\/em> Azad AA, Wyatt AW<\/strong>, Chi KN. Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. <\/a>Ann Oncol. 2021 Jul. doi: 10.1016\/j.annonc.2021.03.205. <\/p>\n\n\n\n

Sperger JM, Emamekhoo H, McKay RR, Stahlfeld CN, Singh A, Chen XE, Kwak L, Gilsdorf CS, Wolfe SK, Wei XX, Silver R, Zhang Z, Morris MJ, Bubley G, Feng FY, Scher HI, Rathkopf D, Dehm SM, Choueiri TK, Halabi S, Armstrong AJ, Wyatt AW,<\/strong> Taplin ME, Zhao SG, Lang JM. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. <\/a>J Clin Oncol. 2021 Jul 1. doi: 10.1200\/JCO.21.00169.<\/p>\n\n\n\n

Herberts C<\/em>, Wyatt AW<\/strong>. Technical and biological constraints on ctDNA-based genotyping. <\/a>Trends Cancer. 2021 Jul. doi: 10.1016\/j.trecan.2021.06.001. <\/p>\n\n\n\n

Clark R, Kenk M, McAlpine K, Thain E, Farncombe KM, Pritchard CC, Nussbaum R, Wyatt AW<\/strong>, de Bono J, Vesprini D, Bombard Y, Lorentz J, Narod S, Kim R, Fleshner N. The evolving role of germline genetic testing and management in prostate cancer: Report from the Princess Margaret Cancer Centre International Retreat. <\/a>Can Urol Assoc J. 2021 Jun;. doi: 10.5489\/cuaj.7383. <\/p>\n\n\n\n

Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW,<\/strong> Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. Differential treatment outcomes in BRCA1\/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. <\/a>Cancer. 2021 Jun 15. doi: 10.1002\/cncr.33487<\/p>\n\n\n\n

Smith MR, Thomas S, Gormley M, Chowdhury S, Olmos D, Oudard S, Feng FY, Rajpurohit Y, Urtishak K, Ricci DS, Rooney B, Lopez-Gitlitz A, Yu M, Wyatt AW<\/strong>, Li M, Attard G, Small EJ. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. <\/a>Clin Cancer Res. 2021 Jun. doi: 10.1158\/1078-0432.CCR-21-0358. <\/p>\n\n\n\n

Annala M<\/em>, Taavitsainen S<\/em>, Khalaf DJ, Vandekerkhove G<\/em>, Beja K<\/em>, Sipola J, Warner EW<\/em>, Herberts C, Wong A,<\/em> Fu S, Finch DL, Oja CD, Vergidis J, Zulfiqar M, Eigl BJ, Kollmansberger CK, Nykter M, Gleave ME, Chi KN, Wyatt AW<\/strong>. Evolution of Castration-Resistant Prostate Cancer in CtDNA during Sequential Androgen Receptor Pathway Inhibition. <\/a>Clin Cancer Res. 2021 Jun 3;. doi: 10.1158\/1078-0432.CCR-21-1625. [Epub ahead of print] PubMed PMID: 34083234.<\/p>\n\n\n\n

Casanova-Salas I, Athie A, Boutros PC, Del Re M, Miyamoto DT, Pienta KJ, Posadas EM, Sowalsky AG, Stenzl A, Wyatt AW<\/strong>, Mateo J. Quantitative and Qualitative Analysis of Blood-based Liquid Biopsies to Inform Clinical Decision-making in Prostate Cancer. <\/a>Eur Urol. 2021 Jun;79(6):762-771. doi: 10.1016\/j.eururo.2020.12.037. Epub 2021 Jan 7. Review. PubMed PMID: 33422353.<\/p>\n\n\n\n

Sumiyoshi T<\/em>, Chi KN, Wyatt AW<\/strong>. Clinical implications of genomic alterations in metastatic prostate cancer. <\/a>Prostate Cancer Prostatic Dis. 2021 Jun;24(2):310-322. doi: 10.1038\/s41391-020-00308-x. Epub 2021 Jan 15. Review. PubMed PMID: 33452452.<\/p>\n\n\n\n

Ng SWS<\/em>, Wyatt AW<\/strong>. Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer. <\/a>Nat Rev Urol. 2021 May;18(5):255-256. doi: 10.1038\/s41585-021-00455-3. PubMed PMID: 33742188.<\/p>\n\n\n\n

De Laere B, Crippa A, Mortezavi A, Ghysel C, Rajan P, Eklund M, Wyatt A,<\/strong> Dirix L, Ost P, Gr\u00f6nberg H, Lindberg J, On Behalf Of The Core And ProBio Investigators. Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer. <\/a>Cancers (Basel). 2021 Mar 30;13(7). doi: 10.3390\/cancers13071588. PubMed PMID: 33808193; PubMed Central PMCID: PMC8037684.<\/p>\n\n\n\n

Warner E*, Herberts C<\/em>*, Fu S, Yip S, Wong A, Wang G, Ritch E, Murtha AJ, Vandekerkhove G, Fonseca NM<\/em>, Angeles A, Beigi A, Sch\u00f6nlau E, Beja K, Annala M<\/em>, Khalaf D, Chi K, Wyatt AW (corresponding author)<\/strong>. BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression. Clin Cancer Res. 2021<\/u><\/em><\/strong>. <\/p>\n\n\n\n

Chen E, Cario CL, Leong L, Lopez K, M\u00e1rquez CP, Chu C, Li PS, Oropeza E, Tenggara I, Cowan J, Simko JP, Chan JM, Friedlander T, Wyatt AW,<\/strong> Aggarwal R, Paris PL, Carroll PR, Feng F, Witte JS. Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. <\/a>Sci Rep. 2021 Mar 3;11(1):5040. doi: 10.1038\/s41598-021-84507-z. PubMed PMID: 33658587; PubMed Central PMCID: PMC7930042.<\/p>\n\n\n\n

Vandekerkhove G,<\/em> Lavoie J, Annala M, Murtha AJ<\/em>, Sundahl N, Walz S, Sano T, Taavitsainen S, Ritch E<\/em>, Fazli L, Hurtado-Coll A, Wang G, Nykter M, Black PC, Todenhofer T, Ost P, Gibb EA, Chi KN, Eigl BJ, Wyatt AW (corresponding author)<\/strong>. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nature Communications 2021.<\/u><\/em><\/strong> <\/p>\n\n\n\n

2020<\/h5>\n\n\n\n

Hofmann MR, Hussain M, Dehm SM, Beltran H, Wyatt AW<\/strong>, Halabi S, Sweeney C, Scher HI, Ryan CJ, Feng FY, Attard G, Klein E, Miyahira A, Soule H, Sharifi N. Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology. 2020<\/u><\/em><\/strong> Dec 26;. doi: 10.1016\/j.urology.2020.12.021<\/p>\n\n\n\n

Fonseca NM<\/em>, Roberts ME, Wyatt AW<\/em> (corresponding author)<\/strong>. A marrow-minded look at immune checkpoint blockade resistance in metastatic castration-resistant prostate cancer. Translational Andrology and Urology 2020<\/u><\/em><\/strong>. Epub ahead of print, retrieved from http:\/\/tau.amegroups.com\/article\/view\/57989\/pdf<\/a><\/p>\n\n\n\n

Vandekerkhove G, Wyatt A<\/strong><\/em> (corresponding author)<\/strong>. (2020). Circulating Tumour DNA as a Biomarker Source in Metastatic Prostate Cancer. Soci\u00e9t\u00e9 Internationale d\u2019Urologie Journal. 2020<\/u><\/em><\/strong> 1(1), 39-48. Retrieved from https:\/\/siuj.org\/index.php\/siuj\/article\/view\/36<\/a><\/p>\n\n\n\n

Kawai Y, Imada K, Akamatsu S, Zhang F, Seiler R, Hayashi T, Leong J, Beraldi E, Saxena N, Kretschmer A, Oo HZ, Contreras-Sanz A, Matsuyama H, Lin D, Fazli L, Collins CC, Wyatt AW<\/strong>, Black PC, Gleave ME. Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. Mol Cancer Ther. 2020<\/u><\/em><\/strong> Oct;19(10):2210-2220. doi: 10.1158\/1535-7163.MCT-19-1031. Epub 2020 Aug 26. PubMed PMID: 32847979<\/p>\n\n\n\n

Khalaf DJ, Arag\u00f3n IM, Annala M,<\/em> Lozano R, Taavitsainen S<\/em>, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cend\u00f3n Y, Oja C, Pacheco MI, Zulfiqar M, Gleave ME, Wyatt AW<\/strong>, Olmos D, Chi KN, Castro E. HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Ann Oncol. 2020<\/u><\/em><\/strong> Sep;31(9):1186-1197. doi: 10.1016\/j.annonc.2020.06.006. PMID: 32574722.<\/p>\n\n\n\n

Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sj\u00f6str\u00f6m M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW<\/strong>, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020<\/u><\/em><\/strong> Aug;52(8):778-789. doi: 10.1038\/s41588-020-0648-8. PMID: 32661416.<\/p>\n\n\n\n

Alcaide M, Cheung M, Hillman J, Rassekh SR, Deyell RJ, Batist G, Karsan A, Wyatt AW<\/strong>, Johnson N, Scott DW, Morin RD. Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. Sci Rep. 2020<\/u><\/em><\/strong> Jul 28;10(1):12564. doi: 10.1038\/s41598-020-69432-x. PMID: 32724107.<\/p>\n\n\n\n

Herberts C, Murtha AJ<\/em>, Fu S, Wang G, Sch\u00f6nlau E,<\/em> Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, Vandekerkhove G, Ritch E, Warner E<\/em>, Saad F, Iqbal N, Nykter M, Gleave ME, Wang Y, Annala M<\/em>, Chi KN, Wyatt AW (corresponding author)<\/strong>. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2020<\/u><\/em><\/strong> May 22;. doi: 10.1016\/j.eururo.2020.04.058. [Epub ahead of print] PMID: 32451180<\/p>\n\n\n\n

Tesch ME, Pater JA, Vandekerkhove G<\/em>, Wang G, Binnington K, So AI, Wyatt AW<\/strong>, Eigl BJ. Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer. NPJ Genom Med. 2020<\/u><\/em><\/strong>;5:12. doi: 10.1038\/s41525-020-0121-8. eCollection 2020. PMID: 32218990.<\/p>\n\n\n\n

Bacon JVW, Annala M<\/em>, Soleimani M, Lavoie JM, So A, Gleave ME, Fazli L, Wang G, Chi KN, Kollmannsberger CK, Wyatt AW(corresponding author)<\/strong>, Nappi L. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2020<\/u><\/em><\/strong> Aug;18(4):322-331.e2. doi: 10.1016\/j.clgc.2019.12.018. PMID: 32046920.<\/p>\n\n\n\n

Ritch E, Fu SYF, Herberts C<\/em>, Wang G, Warner EW, Sch\u00f6nlau E, Taavitsainen S, Murtha AJ, Vandekerkhove G, Beja K, Loktionova Y<\/em>, Khalaf D, Fazli L, Kushnir I, Ferrario C, Hotte S, Annala M<\/em>, Chi KN, Wyatt AW (corresponding author)<\/strong>. Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer. Clin Cancer Res. 2020<\/u><\/em><\/strong> Mar 1;26(5):1114-1125. doi: 10.1158\/1078-0432.CCR-19-1623. PMID: 31744831.<\/p>\n\n\n\n

Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW<\/strong>, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020<\/u><\/em><\/strong> Mar;77(3):333-341. doi: 10.1016\/j.eururo.2019.09.036. PMID: 31640893.<\/p>\n\n\n\n

2019<\/h5>\n\n\n\n

Alshalalfa M, Liu Y, Wyatt AW<\/strong>, Gibb EA, Tsai HK, Erho N, Lehrer J, Takhar M, Ramnarine VR, Collins CC<\/em>, Den RB, Schaeffer EM, Davicioni E, Lotan TL, Bismar TA. Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma. Int J Cancer. 2019<\/u><\/em><\/strong> Dec 15;145(12):3453-3461. doi: 10.1002\/ijc.32430. PMID: 31125117.<\/p>\n\n\n\n

Khalaf DJ, Annala M (co-first)<\/em>, Taavitsainen S<\/em>, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW<\/strong>, Chi KN. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol. 2019<\/u><\/em><\/strong> Dec;20(12):1730-1739. doi: 10.1016\/S1470-2045(19)30688-6. PMID: 31727538. <\/p>\n\n\n\n

Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, O’Neil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW<\/strong>, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C. Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol. 2019<\/u><\/em><\/strong> Nov 20;37(33):3090-3098. doi: 10.1200\/JCO.18.02057. PMID: 31553692.<\/p>\n\n\n\n

Seiler R, Wyatt AW<\/strong>, Black PC. Molecular landscape of carcinoma invading bladder muscle: does patient age matter? BJU Int. 2019<\/u><\/em><\/strong> Nov;124(5):719-721. doi: 10.1111\/bju.14802. PMID: 31074172.<\/p>\n\n\n\n

Dugas SG, M\u00fcller DC, Le Magnen C, Federer-Gsponer J, Seifert HH, Ruiz C, Savic Prince S, Vlajnic T, Zellweger T, Mertz KD, Bacon JVW<\/em>, Wyatt AW<\/strong>, Rentsch CA, Bubendorf L. Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer. Cancer Cytopathol. 2019<\/u><\/em><\/strong> Sep;127(9):578-585. doi: 10.1002\/cncy.22167. PMID: 31386310.<\/p>\n\n\n\n

Genitsch V, Koll\u00e1r A, Vandekerkhove G<\/em>, Blarer J, Furrer M, Annala M, Herberts C,<\/em> Pycha A, de Jong JJ, Liu Y, Krentel F, Davicioni E, Gibb EA, Kruithof-de Julio M, Wyatt AW<\/strong>, Seiler R. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. Urol Oncol. 2019<\/u><\/em><\/strong> Sep;37(9):573.e19-573.e29. doi: 10.1016\/j.urolonc.2019.06.021. PMID: 31358384.<\/p>\n\n\n\n

Taavitsainen S, Annala M, Ledet E, Beja K<\/em>, Miller PJ, Moses M, Nykter M, Chi KN, Sartor O, Wyatt AW (corresponding author)<\/strong>. Evaluation of commercial circulating tumor DNA test in metastatic prostate cancer. JCO Precision Oncology 2019<\/u><\/em><\/strong>, 3: 1-9. doi: 10.1200\/PO.19.00014. (IF pending; citations 9)<\/p>\n\n\n\n

Jayaram A, Wingate A, Wetterskog D, Conteduca V, Khalaf D, Sharabiani MT, Calabr\u00f2 F, Barwell L, Feyerabend S, Grande E, Martinez-Carrasco Am, Font A, Berruti A, Sternberg CN, Jones R, Lefresne F, Lahaye M, Thomas S, Joshi S, Shen D, Ricci D, Gormley M, Merseburger AS, Tombal B, Annala M<\/em>, Chi KN, De Giorgi U, Gonzalez-Billalabeitia E, Wyatt AW<\/strong>, Attard G. Plasma androgen receptor copy number status at emergence of metastatic castration-resistant prostate cancer: A pooled multicohort analysis. JCO Precision Oncology. 2019<\/u><\/em><\/strong> Sep;3:1-3. DOI: 10.1200\/PO.19.00123<\/p>\n\n\n\n

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M<\/em>, Powers J, Wyatt AW<\/strong>, Seymour L. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clin Genitourin Cancer. 2019<\/u><\/em><\/strong> Jun;17(3):201-208.e1. doi: 10.1016\/j.clgc.2019.03.005. PMID: 31056399.<\/p>\n\n\n\n

Warner EW<\/em>, Yip SM<\/em>, Chi KN, Wyatt AW<\/strong>. DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU Int. 2019 May;123(5):769-776. PubMed PMID: 30281887.<\/p>\n\n\n\n

Sundahl N\u2020<\/em>, Vandekerkhove G\u2020<\/em>, Decaestecker K, Meireson A, De Visschere P, Fonteyne V, De Maeseneer D, Reynders D, Goetghebeur E, Van Dorpe J, Verbeke S, Annala M<\/em>, Brochez L, Van der Eecken K, Wyatt AW<\/strong>, Rottey S, Ost P. Randomized Phase 1 Trial of Pembrolizumab with Sequential Versus Concomitant Stereotactic Body Radiotherapy in Metastatic Urothelial Carcinoma. Eur Urol. 2019 May;75(5):707-711. PMID: 30665814. \u2020co-first authors<\/em><\/p>\n\n\n\n

Manogue C, Cotogno P, Ledet E, Lewis B, Wyatt AW<\/strong>, Sartor O. Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. Oncologist. 2019 Apr;24(4):444-448. PMID: 30541755.<\/p>\n\n\n\n

Vandekerkhove G\u2020<\/em>, Struss WJ\u2020<\/em>, Annala M\u2020<\/em>, Kallio HML, Khalaf D<\/em>, Warner EW<\/em>, Herberts C<\/em>, Ritch E<\/em>, Beja K<\/em>, Loktionova Y<\/em>, Hurtado-Coll A, Fazli L, So A, Black PC, Nykter M, Tammela T, Chi KN, Gleave ME, Wyatt AW<\/strong>. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol. 2019 Apr;75(4):667-675. PMID: 30638634. \u2020co-first authors<\/em><\/p>\n\n\n\n

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K<\/em>, Annala M<\/em>, Powers J, Wyatt AW<\/strong>, Seymour L. A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205. Clin Genitourin Cancer. 2019 Mar 15;. [Epub ahead of print] PMID: 31056399.<\/p>\n\n\n\n

2018<\/h5>\n\n\n\n

da Costa JB, Gibb EA, Nykopp TK, Mannas M, Wyatt AW<\/strong>, Black PC. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy. Urol Oncol. 2018 Dec 8;. [Epub ahead of print] PMID: 30528886.<\/p>\n\n\n\n

Annala M<\/em>, Taavitsainen S<\/em>, Vandekerkhove G<\/em>, Bacon JVW<\/em>, Beja K<\/em>, Chi KN, Wyatt AW<\/strong>. Frequent mutation of the FOXA1 untranslated region in prostate cancer. Commun Biol<\/span>. 2018;<\/span>1<\/span>:122<\/span>. PMID: 30272002<\/span>; <\/span><\/p>\n\n\n\n

Lu E, Thomas GV, Chen Y, Wyatt AW<\/strong>, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 Aug;16(8):933-937. PMID: 30099369.<\/p>\n\n\n\n

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW<\/strong>, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 Jul 26;174(3):758-769.e9. PMID: 30033370<\/p>\n\n\n\n

Chedgy EC\u2020<\/em>, Vandekerkhove G\u2020<\/em>, Herberts C\u2020<\/em>, Annala M<\/em>, Donoghue AJ, Sigouros M, Ritch E<\/em>, Struss W<\/em>, Konomura S, Liew J, Parimi S, Vergidis J, Hurtado-Coll A, Sboner A, Fazli L, Beltran H, Chi KN, Wyatt AW<\/strong>. Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma. J Pathol<\/span>. 2018 Oct;<\/span>246<\/span>(2)<\/span>:244-253<\/span>. PMID: 30015382. \u2020co-first authors<\/em><\/p>\n\n\n\n

Park ES, Yan JP, Ang RA, Lee JH, Deng X, Duffy SP, Beja K<\/em>, Annala M<\/em>, Black PC, Chi KN, Wyatt AW<\/strong>, Ma H. Isolation and genome sequencing of individual circulating tumor cells using hydrogel encapsulation and laser capture microdissection. Lab Chip. 2018 Jun 12;18(12):1736-1749. PMID: 29762619<\/p>\n\n\n\n

Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW<\/strong>, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. Gigascience. 2018 Jun 1;7(6). PMID: 29757368<\/p>\n\n\n\n

Goriki A, Seiler R, Wyatt AW<\/strong>, Contreras-Sanz A, Bhat A, Matsubara A, Hayashi T, Black PC. Unravelling disparate roles of NOTCH in bladder cancer. Nat Rev Urol. 2018 Jun;15(6):345-357. PMID: 29643502<\/p>\n\n\n\n

Todenh\u00f6fer T, Struss WJ<\/em>, Seiler R, Wyatt AW<\/strong>, Black PC. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer. 2018 Jan 20;4(1):19-29. PMID: 29430504<\/p>\n\n\n\n

Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW<\/em>, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW*<\/em><\/strong>, Chi KN*<\/em><\/strong>. Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer. Cancer Discov<\/span>. 2018 Apr;<\/span>8<\/span>(4)<\/span>:444-457<\/span>. PMID: 29367197. *co-corresponding authors<\/strong><\/em><\/p>\n\n\n\n

Todenh\u00f6fer T, Struss WJ, Seiler R, Wyatt AW<\/strong>, Black PC. Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. Bladder Cancer<\/span>. 2018 Jan 20;<\/span>4<\/span>(1)<\/span>:19-29<\/span>. PMID: 29430504.<\/p>\n\n\n\n

Vandekerkhove G<\/em>, Chi KN, Wyatt AW<\/strong>. Clinical utility of emerging liquid biomarkers in advanced prostate cancer. Cancer Genet<\/span>. 2018 Dec;<\/span>228-229<\/span>:151-158<\/span>. PMID: 28958406<\/span>.<\/p>\n\n\n\n

Ritch E<\/em>, Wyatt AW<\/strong>. Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. Urol Oncol<\/span>. 2018 Aug;<\/span>36<\/span>(8)<\/span>:380-384<\/span>. PMID: 29248429.<\/p>\n\n\n\n

2017<\/h5>\n\n\n\n

Wyatt AW\u2020*<\/em><\/strong>, Annala M\u2020<\/em>, Aggarwal R, Beja K<\/em>, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093\/jnci\/djx118. PMID: 29206995. \u2020co-first authors; *corresponding author<\/strong><\/em><\/p>\n\n\n\n

Beltran H\u2020, Wyatt AW\u2020<\/strong>, Chedgy EC<\/em>, Donoghue A, Annala M<\/em>, Warner EW<\/em>, Beja K<\/em>, Sigouros M, Mo F, Fazli L, Collins CC, Eastham J, Morris M, Taplin ME, Sboner A, Halabi S, Gleave ME. Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. Clin Cancer Res<\/span>. 2017 Nov 15;<\/span>23<\/span>(22)<\/span>:6802-6811<\/span>. PMID: 28842510. \u2020co-first authors<\/strong><\/em><\/p>\n\n\n\n

Vandekerkhove G<\/em>\u2020, Todenh\u00f6fer T\u2020, Annala M\u2020<\/em>, Struss WJ<\/em>, Wong A<\/em>, Beja K<\/em>, Ritch E<\/em>, Brahmbhatt S, Volik SV, Hennenlotter J, Nykter M, Chi KN, North S, Stenzl A, Collins CC, Eigl BJ, Black PC, Wyatt AW<\/strong>. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clin Cancer Res. 2017 Nov 1;23(21):6487-6497. PMID: 28760909<\/p>\n\n\n\n

Quigley D, Alumkal JJ, Wyatt AW<\/strong>, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K<\/em>, Annala M<\/em>, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 Sep;7(9):999-1005. PMID: 28450426<\/p>\n\n\n\n

Annala M\u2020<\/em>, Struss WJ\u2020<\/em>, Warner EW<\/em>, Beja K<\/em>, Vandekerkhove G<\/em>, Wong A<\/em>, Khalaf D<\/em>, Sepp\u00e4l\u00e4 IL<\/em>, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW<\/strong>. Treatment outcomes and tumor loss-of-heterozygosity in germline DNA repair deficient prostate cancer. Eur Urol<\/span>. 2017 Jul;72(1):34-42. PMID: 28259476. \u2020co-first authors<\/em><\/p>\n\n\n\n

Kiss B, Wyatt AW<\/strong>, Douglas J, Skuginna V, Mo F, Anderson S, Rotzer D, Fleischmann A, Genitsch V, Hayashi T, Neuenschwander M, B\u00fcrki C, Davicioni E, Collins C, Thalmann GN, Black PC, Seiler R. Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. Sci Rep. 2017 Feb 16; 7:42713. PMID: 28205537<\/p>\n\n\n\n

Donmez N, Malikic S, Wyatt AW<\/strong>, Gleave ME, Collins CC, Sahinalp SC. Clonality inference from single tumor samples using low-coverage sequence data. J Comput Biol<\/span>. 2017 Jun;<\/span>24<\/span>(6)<\/span>:515-523<\/span>. PMID: 28056180<\/p>\n\n\n\n

Holt R, Ugur Iseri SA, Wyatt AW<\/strong>, Bax DA, Gold Diaz D, Santos C, Broadgate S, Dunn R, Bruty J, Wallis Y, McMullan D, Ogilvie C, Gerrelli D, Zhang Y, Ragge N. Identification and functional characterisation of genetic variants in OLFM2 in children with developmental eye disorders. Hum Genet<\/span>. 2017 Jan;<\/span>136<\/span>(1)<\/span>:119-127<\/span>.  PMID: 27844144.<\/p>\n\n\n\n

Bishop JL, Thaper D, Vahid S, Davies A, Ketola K, Kuruma H, Jama R, Nip KM, Angeles A, Johnson F, Wyatt AW<\/strong>, Fazli L, Gleave ME, Lin D, Rubin MA, Collins CC, Wang Y, Beltran H, Zoubeidi A. The Master Neural Transcription Factor BRN2 is an Androgen Receptor Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer. Cancer Discov<\/span>. 2017 Jan;<\/span>7<\/span>(1)<\/span>:54-71<\/span>. PMID: 27784708.<\/p>\n\n\n\n

Kockan C, Hach F, Sarrafi I, Bell RH, McConeghy B, Beja K<\/em>, Haegert A, Wyatt AW<\/strong>, Volik SV, Chi KN, Collins CC, Sahinalp SC. SiNVICT: Ultra-Sensitive Detection of Single Nucleotide Variants and Indels in Circulating Tumour DNA. Bioinformatics<\/span>. 2017 Jan 1;<\/span>33<\/span>(1)<\/span>:26-34<\/span>. PMID: 27531099.<\/p>\n\n\n\n

2016<\/h5>\n\n\n\n

Saranchova I, Han J, Huang H, Choi KB, Munro L, Pfeifer C, Welch I, Wyatt AW<\/strong>, Fazli L, Gleave ME, Jefferies WA. Discovery of a Novel Mechanism of Cancer Immune Escape Guided by the Loss of Interleukin-33 Expression. Sci Rep. 2016 Sep 13;6:30555. PMID: 27619158.<\/p>\n\n\n\n

Lowes LE, Bratman SV, Dittamore R, Done S, Kelley SO, Mai S, Morin RD, Wyatt AW<\/strong>, Allan AL. Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci. 2016 Sep 8;17(9). pii: E1505. PMID: 27618023.<\/p>\n\n\n\n

Annala M<\/em>, Nappi L, Azad AA, Mo F, Fazli L, Chi KC, Wyatt AW<\/strong>. Molecular dissection of complete response to receptor tyrosine kinase inhibition in type II papillary renal cell carcinoma. Clinical Genitourinary Cancer 2016. pii: S1558-7673(16)30145-8.<\/p>\n\n\n\n

Wyatt AW\u2020<\/strong>, Azad AA\u2020, Volik SV\u2020, Annala M, Beja K, McConeghy B, Haegert A, Warner EW, Mo F, Brahmbhatt S, Shukin R, Le Bihan S, Gleave ME, Nykter M, Collins CC, Chi KN. Genomic alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncology 2016. 2(12):1598-1606. PMID: 27148695. \u2020co-first authors<\/strong><\/em><\/p>\n\n\n\n

Lallous N, Volik SV, Awrey S, Leblanc E, Tse R, Murillo J, Singh K, Azad AA, Wyatt AW<\/strong>, LeBihan S, Chi KN, Gleave ME, Rennie PS, Collins CC, Cherkasov A. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biology 2016. 17(1):10. PMID:26813233.<\/p>\n\n\n\n

Hayashi T, Gust KM, Wyatt AW<\/strong>, Goriki A, J\u00e4ger W, Awrey S, Li N, Oo HZ, Altamirano-Dimas M, Buttyan R, Fazli L, Matsubara A, Black PC. Not all Notch is created equal: the oncogenic role of NOTCH2 in bladder cancer and its implications for targeted therapy. Clin Cancer Res<\/span>. 2016 Jun 15;<\/span>22<\/span>(12)<\/span>:2981-92<\/span>. PMID: 26769750<\/span>.<\/p>\n\n\n\n

Chedgy ECP<\/em>, Annala M<\/em>, Beja K<\/em>, Warner EW<\/em>, Gleave ME, Chi KN, Wyatt AW<\/strong>. Moving towards personalized care: liquid biopsy predicts response to cisplatin in an unusual case of BRCA2-null neuroendocrine prostate cancer. Clinical Genitourinary Cancer 2016. 14(2):e233-6. PMID: 26797585<\/p>\n\n\n\n

Selected articles prior to 2015<\/h5>\n\n\n\n

Akamatsu S\u2020, Wyatt AW<\/strong>\u2020, Lin D, Lysakowski S, Zhang F, Kim S, Tse C, Wang K, Mo F, Haegert A, Brahmbhatt S, Bell R, Adomat H, Fazli L, Kawai Y, Xue H, Dong X, Fazli L, Tsai H, Lotan TL, Kossai M, Mosquera JM, Rubin MA, Beltran H, Zoubeidi A, Wang Y, Gleave ME, Collins CC. The placental gene PEG10 promotes progression of neuroendocrine prostate cancer. Cell Reports 2015. Aug 11;12(6):922-36. PMID:26235627. \u2020co-first authors<\/strong><\/em><\/p>\n\n\n\n

Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW<\/strong>, Collins LL, Saad F. Treatment of mCRPC in the AR axis-targeted therapy resistant state. Annals of Oncology 2015 Oct; 26(10):2044-56. PMID: 26101426.<\/p>\n\n\n\n

Wyatt AW<\/strong>, Gleave ME. Targeting the adaptive molecular landscape of castration resistant prostate cancer. EMBO Molecular Medicine 2015 Apr 20;7(7):878-94. PMID: 25896606.<\/p>\n\n\n\n

Azad AA\u2020, Volik SV\u2020, Wyatt AW<\/strong>\u2020, Haegert A, Le Bihan S, Bell RH, Anderson S, McConeghy B, Shukin R, Bazov J, Youngren J, Paris PL, Thomas GV, Small EJ, Wan Y, Gleave ME, Collins CC, Chi KN. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance and response in castration-resistant prostate cancer. Clin Cancer Res 2015 May 15;21(10):2315-24. PMID: 25712683. \u2020co-first authors<\/strong><\/em><\/p>\n\n\n\n

Wyatt AW<\/strong>, Mo F, Wang K, McConeghy B, Brahmbhatt S, Jong L, Mitchell DM, Johnston RL, Haegert A, Li E, Liew J, Yeung J, Shrestha R, Lapuk A, McPherson A, Shukin R, Bell RH, Anderson S, Bishop J, Hurtado-Coll A, Xiao H, Chinnaiyan A, Mehra R, Lin D, Wang Y, Fazli L, Gleave ME, Volik SV, Collins CC. Heterogeneity in the inter-tumor transcriptome of high risk prostate cancer. Genome Biol 2014 Aug 26;15(8):426. PMID: 25155515.<\/p>\n\n\n\n

Lin D\u2020<\/sup>, Wyatt AW<\/strong>\u2020<\/sup>, Xue H, Wang Y, Dong X, Haegert A, Wu R, Brahmbhatt B, Mo F, Jong L, Bell RH, Anderson S, Hurtado-Coll A, Fazli L, Sharma M, Beltran H, Rubin M, Cox M, Gout PW, Morris J, Goldenberg L, Volik SV, Gleave ME, Collins CC, Wang Y. High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. Cancer Research 2014 Feb 15;74(4):1272-83. PMID: 24356420. \u2020co-first authors<\/strong><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

An up-to-date list of our journal publications can be found\u00a0on PubMed\u00a0or Google Scholar. This page was last updated in July…<\/p>\n","protected":false},"author":38238,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-7","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/pages\/7","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/users\/38238"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/comments?post=7"}],"version-history":[{"count":80,"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/pages\/7\/revisions"}],"predecessor-version":[{"id":690,"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/pages\/7\/revisions\/690"}],"wp:attachment":[{"href":"https:\/\/blogs.ubc.ca\/wyattlab\/wp-json\/wp\/v2\/media?parent=7"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}